<?xml version="1.0"?>
<rss version="0.91" encoding="ISO_8859-1"><channel><title>alznews.org</title><link>http://alznews.org</link><description></description><language>en-us</language><copyright>Copyright &amp;copy; 1999-2005 Ageless Design, Inc.</copyright><pubDate>9/2/2010 3:46:58 PM</pubDate><image><title>Sponsored by the Alzheimer's store</title><url>http://www.agelessdesign.com/Library/Images/ImageLibrary/alzstore-logo.gif</url><link>http://alzstore.com</link></image><item><title>Brain Exercise May Worsen Existing Alzheimer's</title><link>http://alznews.org/FolderID/53/InfoID/8177/RedirectPath/Add1/PageVars/Library/InfoManage/Zoom.htm</link><description>(Source: Neurology) - Keeping mentally active may help stave off Alzheimer's disease, but once patients are diagnosed with the condition, "brain exercise" may actually speed up cognitive decline, researchers said. </description></item><item><title>Finding Suggests New Aim for Alzheimer's Drugs</title><link>http://alznews.org/FolderID/53/InfoID/8178/RedirectPath/Add1/PageVars/Library/InfoManage/Zoom.htm</link><description>(Source: New York Times) - In a year when news about Alzheimer's disease seems to alternate between encouraging and disheartening, a new discovery by an 84-year-old scientist has illuminated a new direction.</description></item><item><title>Drug-Candidate Effective in Alzheimer's Disease Model</title><link>http://alznews.org/FolderID/53/InfoID/8179/RedirectPath/Add1/PageVars/Library/InfoManage/Zoom.htm</link><description>(Source: Marketwire) - Addex Pharmaceuticals announced that it has observed efficacy in a model of Alzheimer's disease using a recently discovered available drug-candidate. The proprietary molecule inhibits a receptor called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM).</description></item><item><title>Eisai Announces Start of Clinical Study of BAN2401</title><link>http://alznews.org/FolderID/53/InfoID/8181/RedirectPath/Add1/PageVars/Library/InfoManage/Zoom.htm</link><description>(Source: Marketwatch) - Pharmaceutical company Eisai announced the start of the first patient enrolled clinical study of BAN2401, a novel monoclonal antibody being developed as a potential treatment for Alzheimer's disease.</description></item><item><title>JK Rowling Donates Millions for Neurological Research Clinic</title><link>http://alznews.org/FolderID/53/InfoID/8180/RedirectPath/Add1/PageVars/Library/InfoManage/Zoom.htm</link><description>(Source: Luxist) - &amp;lt;EM&amp;gt;Harry Potter&amp;lt;/EM&amp;gt; author J.K. Rowling has donated more than $15 million for research on degenerative neurological conditions and diseases. The neurology clinic will be based at the University of Edinburgh and will research a variety of diseases, including Alzheimer's and Parkinson's. 
&amp;lt;P&amp;gt;&amp;nbsp;&amp;lt;/P&amp;gt;</description></item></channel></rss>
